Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α.

Aljabali, AAA; Bakshi, HA; Hakkim, FL; Haggag, YA; Al-Batanyeh, KM; Al Zoubi, MS; Al-Trad, B; Nasef, MM; Satija, S; Mehta, M; Pabreja, K; Mishra, V; Khan, M; Abobaker, S; Azzouz, IM; Dureja, H; Pabari, RM; Dardouri, AAK; Kesharwani, P; Gupta, G; Dhar Shukla, S; Prasher, P; Charbe, NB; Negi, P; Kapoor, DN; Chellappan, DK; Webba da Silva, M; Thompson, P; Dua, K; McCarron, P; Tambuwala, MM

Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α.

Aljabali, AAA Bakshi, HA Hakkim, FL Haggag, YA Al-Batanyeh, KM Al Zoubi, MS Al-Trad, B Nasef, MM Satija, S

Mehta, M Pabreja, K Mishra, V Khan, M Abobaker, S Azzouz, IM Dureja, H Pabari, RM Dardouri, AAK Kesharwani, P Gupta, G Dhar Shukla, S Prasher, P Charbe, NB Negi, P Kapoor, DN Chellappan, DK Webba da Silva, M Thompson, P Dua, K

McCarron, P Tambuwala, MM

Permalink

Publisher:: MDPI
Publication Type:: Journal Article
Citation:: Cancers, 2020, 12, (1)
Issue Date:: 2020-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (4.98 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Aljabali, AAA
dc.contributor.author	Bakshi, HA
dc.contributor.author	Hakkim, FL
dc.contributor.author	Haggag, YA
dc.contributor.author	Al-Batanyeh, KM
dc.contributor.author	Al Zoubi, MS
dc.contributor.author	Al-Trad, B
dc.contributor.author	Nasef, MM
dc.contributor.author	Satija, S https://orcid.org/0000-0003-4702-6534
dc.contributor.author	Mehta, M
dc.contributor.author	Pabreja, K
dc.contributor.author	Mishra, V
dc.contributor.author	Khan, M
dc.contributor.author	Abobaker, S
dc.contributor.author	Azzouz, IM
dc.contributor.author	Dureja, H
dc.contributor.author	Pabari, RM
dc.contributor.author	Dardouri, AAK
dc.contributor.author	Kesharwani, P
dc.contributor.author	Gupta, G
dc.contributor.author	Dhar Shukla, S
dc.contributor.author	Prasher, P
dc.contributor.author	Charbe, NB
dc.contributor.author	Negi, P
dc.contributor.author	Kapoor, DN
dc.contributor.author	Chellappan, DK
dc.contributor.author	Webba da Silva, M
dc.contributor.author	Thompson, P
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	McCarron, P
dc.contributor.author	Tambuwala, MM
dc.date.accessioned	2020-07-29T01:47:26Z
dc.date.available	2019-12-12
dc.date.available	2020-07-29T01:47:26Z
dc.date.issued	2020-01
dc.identifier.citation	Cancers, 2020, 12, (1)
dc.identifier.issn	2072-6694
dc.identifier.issn	2072-6694
dc.identifier.uri	http://hdl.handle.net/10453/141902
dc.description.abstract	Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC-BSA nanoparticles (NPs). These PIC-BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC-BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC-BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC-BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC-BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.
dc.format	Electronic
dc.language	eng
dc.publisher	MDPI
dc.relation.ispartof	Cancers
dc.relation.isbasedon	10.3390/cancers12010113
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.title	Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α.
dc.type	Journal Article
utslib.citation.volume	12
utslib.location.activity	Switzerland
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2020-07-29T01:47:20Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	12
utslib.citation.issue	1

Abstract:

Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC-BSA nanoparticles (NPs). These PIC-BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC-BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC-BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC-BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC-BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/141902